Semaglutide vs Tirzepatide: GLP-1 Class Option ஒப்பீடு

Each medicine body work how?

Semaglutide selective GLP-1 receptor agonist. Glucagon-like peptide-1 mimic glucose-dependent insulin secretion enhance, glucagon suppress, gastric emptying slow, appetite reduce. Tirzepatide dual GIP (glucose-dependent insulinotropic polypeptide), GLP-1 receptor agonist—"twincretin" sometimes. GIP receptor activation insulin sensitivity, fat metabolism beyond GLP-1 complementary effect add may. Both diabetes, obesity approved formulation weekly subcutaneous injection synthetic peptide. Neither insulin. Both simply "GLP-1 shot" refer confusion prevent— incretin umbrella share distinct pharmacology. Indian patient both Schedule H prescription CDSCO-approved licenced pharmacy sourcing require.

GIP

Glucose-dependent insulinotropic polypeptide—gut incretin insulin stimulate; tirzepatide GIP, GLP-1 receptor both activate.

Major clinical trial show what?

Tirzepatide SURMOUNT, SURPASS trial obesity, type 2 diabetes population substantial weight loss, HbA1c reduction. Semaglutide STEP, SUSTAIN programme similarly impressive somewhat different magnitude population, dose depend. Head-to-head SURMOUNT-2 tirzepatide semaglutide 1 mg type 2 diabetes compare studied dose greater mean HbA1c, weight reduction. Trial population every Indian patient identical not—genetics, baseline BMI, diet, adherence, South Asia common thin-fat metabolic pattern real-world outcome influence. Indian registry data still accumulate. Trial drug-class efficacy prove; individual response vary. Neither lifestyle intervention replace; neither scale specific number guarantee. High-impact journal publication every patient newest molecule access mean not—access, equity, long-term affordability Indian practice central. Trial subgroup South Asian participant often underrepresent; extrapolation clinical judgement automatic adoption not.

Semaglutide vs tirzepatide overview

• Factor: Receptor target — Semaglutide: GLP-1 only — Tirzepatide: GIP + GLP-1
• Factor: Typical dosing — Semaglutide: Weekly injection (or daily oral) — Tirzepatide: Weekly injection
• Factor: India monthly cost (approx.) — Semaglutide: ₹8,000–₹18,000 — Tirzepatide: ₹15,000–₹25,000
• Factor: Generic available — Semaglutide: Yes (CDSCO-approved) — Tirzepatide: Limited
• Factor: Oral option — Semaglutide: Yes (oral semaglutide) — Tirzepatide: No (injection only)
• Factor: RSSDI positioning — Semaglutide: Established in T2D pathway — Tirzepatide: Newer option when targets unmet

Weight loss, blood sugar compare how?

Average tirzepatide trial higher studied dose obesity population semaglutide 2.4 mg compare somewhat greater mean weight reduction; some diabetes head-to-head greater HbA1c drop. "Average trial result" any single patient promise not. Some semaglutide robust respond tirzepatide plateau; others one molecule only tolerate. Baseline HbA1c, diabetes duration, insulin use, concurrent medicine matter. RSSDI individualised target emphasise—affordable semaglutide HbA1c 9.5% to 7.8% clinically excellent tirzepatide theoretically 7.2% reach may. Metabolic health improve beyond weight loss not always necessary. Doctor efficacy cost, side effect, patient preference balance.

Typical trial outcome (population average, individual promise not)

• Outcome: Mean weight loss (obesity trials) — Semaglutide (STEP/SUSTAIN): Roughly 10–15% body weight at higher doses — Tirzepatide (SURMOUNT/SURPASS): Roughly 15–20% at higher studied doses
• Outcome: HbA1c reduction (T2D) — Semaglutide (STEP/SUSTAIN): Often 1.0–1.5 percentage points — Tirzepatide (SURMOUNT/SURPASS): Often 1.5–2.0+ points in some trials
• Outcome: Time to titrate — Semaglutide (STEP/SUSTAIN): Months of gradual dose increases — Tirzepatide (SURMOUNT/SURPASS): Months of gradual dose increases
• Outcome: Lifestyle required — Semaglutide (STEP/SUSTAIN): Yes—diet and activity — Tirzepatide (SURMOUNT/SURPASS): Yes—diet and activity

Side effect, tolerability expect?

Both similar GI effect—nausea, diarrhoea, constipation—dose escalation most prominent. Titration schedule product differ; either rush poor tolerance, early discontinuation. Gallbladder event, pancreatitis precaution both class. Thyroid C-cell tumour precaution (MTC/MEN2 history) class warning. Weekly pen injection-site reaction uncommon. Semaglutide tolerate not tirzepatide vice versa some; medical supervision without switch—social media anecdote not. Oral semaglutide injection-averse alternative route; tirzepatide India currently lack. Smaller Indian meal, fried avoid, gradual dose increase nausea management both equally apply.

Cardiovascular, kidney factor choice influence?

Semaglutide high-risk type 2 diabetes established atherosclerotic disease extensive cardiovascular outcome trial data. Tirzepatide cardiovascular outcome data mature continue. Both class chronic kidney disease stage glycaemic, weight goal incretin therapy warrant often prefer; individual eGFR, albuminuria dosing guide. Heart failure, gastroparesis, pancreatitis history either limit/contraindicate. Thyroid cancer family history careful specialist review. High cardiovascular burden affordability constraint Indian patient trial-proven MACE benefit align semaglutide start may. Semaglutide maximally tolerated dose agreed target fail tirzepatide escalation sometimes consider.